Evidence map›Paper›PMID 25163630›Full record

ArticleMolecular biology reports2014

Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.

R Salazar-González, R Gómez, S Romano-Moreno, S Medellín-Garibay, A Núñez-Ruíz, M Magaña-Aquino, R C Milán-Segovia, D P Portales-Pérez

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Pharmacogenomic heterogeneity ofAnnals of medicine · 2025
    Observational
  2. Variants in theJournal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. BioMed research international · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

R Salazar-GonzálezLaboratorio de Biofarmacia y Farmacocinética, Facultad de Ciencias Químicas, UASLP, San Luis Potosí, SLP, Mexico.
R Gómez
S Romano-Moreno
S Medellín-Garibay
A Núñez-Ruíz
M Magaña-Aquino
R C Milán-Segovia
D P Portales-Pérez
Autonomous University of San Luis Potosí · MXCenter for Research and Advanced Studies of the National Polytechnic Institute · MXHospital Central Dr. Ignacio Morones Prieto · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arylamine N-acetyltransferase 2 (NAT2) metabolizes isoniazid (INH) and Single Nucleotide Polymorphisms (SNP) responsible for its activity has been reported. The aim of this study in the Mexican mestizo population was to evaluate NAT2 expression at the protein level in immune cells, as well as the distribution and frequency of six NAT2 SNPs and their association with anti-TB therapy, by measuring the plasma levels of INH and Acetyl-INH (AcINH). We performed genotyping assays of NAT2 SNPs in 40 TB patients and 121 healthy volunteers by real-time PCR. A method for detecting NAT2 in immune cells using flow cytometry was developed. Plasma concentrations of INH and AcINH were obtained by HPLC in TB patients and the Metabolic Ratio (MR) was calculated. The phenotypes obtained in the healthy volunteers were as follows; 18.87 % of subjects had the rapid acetylator phenotype, 45.45 % had the intermediate phenotype and 39.66 % exhibited the slow acetylator phenotype. In the TB patient group, 35 % of patients had the rapid acetylator phenotype, 32.5 % were intermediate and 32.5 % showed the slow acetylator phenotype. A higher expression level of NAT2 in innate immune cells from TB patients compared to those from healthy volunteers was detected (P < 0.013). In TB patients the MR showed a bimodal distribution with an antimode of 0.7, which was used as a threshold value for acetylator classification. A high correspondence between the rapid and slow acetylator phenotype with MR was demonstrated. In conclusion, the 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, 857G>A SNPs of NAT2 gene provides accurate for prediction of the acetylator phenotype in Mexican mestizo population. A statistical difference was found in frequency of rapid metabolizer phenotype, which was higher in TB patients. In addition, the expression of NAT2 protein in immune cells can lead to further studies related to its functional role in the innate immune response against M. tuberculosis and other xenobiotics metabolized by this enzyme.

Indexed as

Polymorphism, Single NucleotideAdultAnimalsAntitubercular AgentsArylamine N-AcetyltransferaseCHO CellsCricetulusFemaleHeLa CellsHumansIsoniazidLymphocytesMaleMexicoMiddle AgedTuberculosisAntitubercular AgentsArylamine N-AcetyltransferaseIsoniazidNAT2 protein, human

Identifiers

PMID25163630
OpenAlexW2154724108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.